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The ability of human neutrophil elastase and cathepsin G to activate matrix metaUoproteinase 3 (MMP-3 = stromelysin) 
and MMP-2 ('gelatinase') purified from human rheumatoid synovial flbroblasts in cultu e was examined. The zymogen 
of MMP-3 (proMMP-3) was activated tofull activity with elastase and cathepsin G by limited proteolysis of the molecule 
into two active forms of M,~45000 and Mr~25000. In contrast, proMMP-2 was not activated at all by these n utrophil 
serine proteinases, although it was degraded into small fragments. These data suggest that neutrophil elastase and cath- 
epsin G may play an important role in the activation f proMMP-3 in vivo in various inflammatory conditions, but 
proMMP-2 may be activated in different ways. 
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1. INTRODUCTION 
Rheumatoid synovial fibroblasts in culture 
secrete three distinct matrix metalloproteinases 
(MMPs): MMP-1 corresponds to collagenase (EC 
3.4.24.7) [1], MMP-2 to 'gelatinase' and type IV 
collagenase [2-5] and MMP-3 to stromelysin 
[6-8]. Collagenase digests type I, II, I I I  and X [9] 
collagens. MMP-2 is thought o be involved in the 
degradation of collagen by digesting elatin deriv- 
ed from collagen molecules cleaved by the action 
of collagenase [2], although the ability of the en- 
zyme to digest type IV and type V collagens has 
been pointed out [4,5]. MMP-3 has a broad range 
of activities to extracellular macromolecules; it 
degrades proteoglycans, type IV collagen, laminin, 
fibronectin and gelatin, and removes N-terminal 
propeptides of type I procollagen [6-8]. We have 
recently demonstrated that MMP-3 also digests 
type IX collagen which has an important role in 
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maintaining the structural integrity of cartilage 
[10]. The synthesis and secretion of the proteinase 
by synovial lining cells in rheumatoid synovium 
have been shown by immunohistochemical studies 
[ l l ] .  
MMP-3 and MMP-2 as well as collagenase are, 
however, secreted in inactive proenzymes 
(proMMPs) which are then activated extracellular- 
ly [4,5,12-14]. Thus, their activation is a key pro- 
cess for them to participate in the degradation of 
extracellular matrix components in vivo. We 
report here that proMMP-3 is activated by human 
neutrophil elastase and cathepsin G by limited pro- 
teolysis, but proMMP-2 is not. 
2. MATERIALS AND METHODS 
2.1. Materials 
ProMMP-3 was purified from the culture medium of 
rheumatoid synovial cells treated with rabbit macrophage- 
conditioned medium as reported [14]. ProMMP-2 was also 
isolated from the above-mentioned culture medium (Okada, Y. 
et al., manuscript n preparation). Both proMMP-3 and 
proMMP-2 were homogeneous according to SDS-polyacryl- 
amide gel electrophoresis (SDS-PAGE). Human neutrophil 
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elastase [15] and cathepsin G [16] were generous gifts from Dr 
J. Travis, Department of Biochemistry, University of Georgia, 
Athens, GA, USA. Diisopropyl fluorophosphate and 
4-aminophenylmercuric acetate (NH2PhHgAc) were obtained 
from Sigma. 
2.2. Activation of proMMP-3 and proMMP-2 by human 
neutrophil elastase and cathepsin G 
The activation f proMMP-3 and proMMP-2 by neutrophil 
serine protelnases was investigated as follows: proMMP-3 
(180 ng) and proMMP-2 (50 ng) in 10/A of 50 mM Tris-HC1, 
pH 7.5, 0.15 M NaC1, 10 mM Ca 2+, 0.02070 NAN3, 0.05o70 Brij 
35 were reacted with an equal volume of human eutrophil 
elastase (0.1, 1, 10/zg/ml) or cathepsin G (0.1, 1, 10/~g/ml) at 
37°C for 5 min-24 h. After blocking the activity of he serine 
proteinases with 3.0 mM diisopropyl fluorophosphate (for 
30 min at 23°C), the activities of MMP-3 and MMP-2 were 
assayed by incubation for 1.5 h at 37°C using [3H]carbox- 
ymethylated transferrin and [~4C]gelatin as substrates for 
MMP-3 and MMP-2, respectively [8]. The activation rate f
proMMP-3 and proMMP-2 was determined in comparison with 
the full activities obtained from the samples incubated before 
assays with 1.5 mM NH2PhHgAc for 24 h at 37°C for 
proMMP-3 and with 1.0 mM NH2PhHgAc for 10 rain at 37°C 
for proMMP-2. 
2.3. Electrophoretic analyses of Mr changes of proMMP-3 and 
proMMP-2 
ProMMP-3 (2.7/zg) and proMMP-2 (3.6/zg) were 
radioiodinated according to Fraker and Speck [17]. Mixtures 
containing unlabeled proMMP-3 (162 ng) and 125I-labeled 
proMMP-3 (10 ng), and unlabeled proMMP-2 (50 ng)and 125I- 
labeled proMMP-2 (11 ng) were treated with human eutrophil 
elastase (10/Lg/ml) or cathepsin G (10/~g/ml) for 10 rain-22 h 
at 37°C. After the incubation, the protelnase activities were in- 
activated using 4.5 mM diisopropyl fluorophosphate and 
40 mM EDTA. Proteins in the samples were resolved by SDS- 
PAGE using 10070 polyacrylamide g ls with reduction with 
2-mercaptoethanol. Gels were dried and autoradiographed. 
3. RESULTS AND DISCUSSION 
Incubat ion of proMMP-3 with human neutro- 
phil elastase at a concentrat ion of 10/~g/ml 
resulted in almost full activation in 2 h at 37°C and 
the MMP-3 activity remained stable after a 24 h in- 
cubat ion (fig.la). At a lower concentrat ion of 
elastase (1/~g/ml), proMMP-3 was gradually ac- 
tivated up to 75% of the full activity, but the en- 
zyme at the concentrat ion of 0.1/zg/ml did not 
significantly activate proMMP-3 compared with a 
buffer control which showed minimal  spontaneous 
activation (15% of full activity) after 24 h at 37°C 
(fig. la). Analyses of 125I-labeled proMMP-3 after 
the reaction with neutrophil  elastase (10/~g/ml) 
showed that proMMP-3 of Mr 57000 was pro- 
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Fig. 1. Activation of proMMP-3 by human eutrophil elastase. 
(a) ProMMP-3 was incubated with elastase t various 
concentrations (zx, 0; A, 0.1; o, 1; e, 10/zg/ml). After 
inactivating the serine proteinase, the activity of MMP-3was 
assayed. The activity of MMP-3 obtained from samples 
incubated with 1.5 mM NH2PhHgAc for 24 h at 37°C was 
taken as 100070 activity. (b) A mixture of unlabeled and 125I- 
labeled proMMP-3 was incubated with neutrophil elastase 
(10/~g/ml). Samples were subjected on SDS-PAGE (10% total 
aerylamide) under the reduction a d the gels autoradiographed. 
Lanes: 1,7, proMMP-3 incubated without enzyme for 0 and 
22 h; 2-6, proMMP-3 treated with the enzyme for 10 min, 1, 
4, 8 and 22 h, respectively. Mr values (x 10 -3) given to the left 
of the gel. 
cessed to a polypeptide of Mr 45 000 with an in- 
termediate form of Mr 49000 and into a doublet of 
M, 25 000 and 23 000 (fig. l b). The lower intensity 
of radioactivity of activated fragments i probably 
354 
Volume 249, number 2 FEBS 
due to the smaller amount of 125I-labeling in these 
regions. 
Neutrophil cathepsin G (10/zg/ml) also ac- 
tivated proMMP-3 to full activity of the enzyme, 
although the time course of the activation was 
rather gradual. It required a 22 h incubation at 
37°C for full activity (fig.2a). At a concentration 
of 1/zg/ml, only partial activation f proMMP-3 
(up to 35°7o) was observed but no significant ac- 
tivation was observed at a concentration of 
0.1/zg/ml even after a 22 h incubation at 37°C 
(fig.2a). SDS-polyacrylamide g l electrophoresis 
showed that neutrophil cathepsin G (10/zg/ml) 
converted proMMP-3 into a polypeptide of Mr 
46000 and then i to a major fragment of Mr 26000 
(fig.2b). 
In contrast to the effective activation of 
proMMP-3 by neutrophil elastase and cathepsin 
G, proMMP-2 was not activated at all by these 
neutrophil serine proteinases atany concentrations 
(0.1, 1 and 10/~g/ml). When t25I-labeled 
proMMP-2 was incubated with elastase (10/~g/ml) 
at 37°C, the zymogen of Mr 74000 was degraded 
into major fragments of Mr 45000, 40000 and 
18 000. Similar findings were made with neutrophil 
cathepsin (3 (10/~g/ml) except that the smaller 
fragments generated were of Mr 43000, 24000, 
19 000 and 17 000. 
It has been reported that the zymogens of col- 
lagenase and MMP-3 are activated ither by direct 
limited proteolysis by endopeptidases including 
trypsin, ~-chymotrypsin, plasma kallikrein, plas- 
min, thermolysin and cathepsin B [12-14,18,19], 
or, alternatively, by mercurial compounds such as 
NH2PhHgAc that may cause certain conforma- 
tional changes in the molecule [12-14]. The present 
study has shown for the first time that 
proMMP-3 can be activated with elastase and 
cathepsin G from human neutrophils. It is clear 
from our study that these serine proteinases ac- 
tivate proMMP-3 by achieving its limited pro- 
teolysis. The comparison of the enzymic activity 
and the fragments produced by these serine pro- 
teinases leads us to the conclusion that the poly- 
peptides of Mr -45 000 and -25 000 are responsible 
for the activity. A similar finding has been ob- 
tained in the case of proMMP-3 activation by 
plasmin [14]. These serine proteinases activate 
proMMP-3 to active forms with lower Mr values by 
the removal of N-terminal and C-terminal frag- 
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Fig.2. Activation of proMMP-3 by human neutrophil cathepsin 
G. (a) ProMMP-3 was incubated with cathepsin G at different 
concentrations ( t , ,  0; • ,  0.1; o, 1; i ,  10/zg/ml). Activation 
rate of proMMP-3 was measured as described in the legend to 
fig. la. (b) A mixture of unlabeled and 125I-labeled proMMP-3 
was treated with neutrophil cathepsin G (10/Lg/ml) and 
analyzed by SDS-PAGE as described in the legend to fig.lb. 
Lanes: 1, proMMP-3 incubated without enzyme for 0 h, 2-6, 
proMMP-3 treated with the enzyme for 10 min, 1, 4, 8 and 
24 h, respectively. Mr values (x 10 -3) given to the left. 
ments from the precursor, since the amino acid se- 
quence thought o be involved in binding a zinc 
atom is located approximately in the middle of 
proMMP-3 [20]. 
Plasmin has been considered to be a good can- 
didate as an activator of proMMP-3 or pro- 
collagenase in vivo [14,18,19]. The present study, 
however, indicates that neutrophil elastase and 
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cathepsin G are also good activators of  
p roMMP-3 .  Tissue inhibitor of  metal loproteinases 
(T IMP) ,  a specific inhibitor of  MMPs ,  is destroyed 
completely by neutrophi l  elastase and part ia l ly by 
cathepsin G, but not by plasmin [21]. Taken 
together,  both elastase and cathepsin G which can 
be suppl ied f rom neutrophi ls  inf i l trated in 
rheumato id  jo int  cavity [22] may play important  
roles in regulat ion of  MMP-3  activity by both ac- 
t ivat ion of  the zymogen and inactivat ion of  T IMP.  
It is of  interest hat p roMMP-2  is not activated 
with neutrophi l  elastase or cathepsin G. The en- 
zyme is readi ly act ivated with NH2PhHgAc  [4,5] 
p robab ly  by changes in the molecular  conforma-  
t ion as reported in the act ivat ion of  procol lagenase 
and proMMP-3  [12-14]. However,  the data that 
serine proteinases uch as trypsin [4,5] as well as 
neutrophi l  elastase and cathepsin G reported here 
cannot  activate proMMP-2  suggest hat different 
mechanisms are invol'~ed in the act ivat ion of  this 
metal loproteinase.  Further  work is necessary to 
elucidate the act ivat ion mechanisms of  p roMMP-2  
in vivo. 
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